News Release

New strategy may help prevent kidney failure in patients with diabetes

Investigational compound slows kidney disease progression in mice

Peer-Reviewed Publication

American Society of Nephrology


  • A newly developed compound inhibits the deleterious effects of high blood sugar on kidney cells and slows the progression of kidney disease in diabetic mice.
  • The compound protects the kidneys in both early and advanced phases of diabetes, and it reduces expression of genes associated with kidney inflammation and scarring.
  • Diabetes is the most common cause of kidney failure.

Washington, DC (September 8, 2016) -- A new strategy may help halt the progression of kidney disease in patients with diabetes. The approach, which is highlighted in an upcoming issue of the Journal of the American Society of Nephrology (JASN), addresses a common and serious complication of diabetes.

Diabetes is the leading cause of chronic kidney disease and kidney failure, and approximately one-third of diabetic patients develop kidney disease, or diabetic nephropathy. Current diabetes therapies are often insufficient for preventing the progression of diabetic nephropathy to kidney failure, but a team led by Jesus Egido, MD, PhD and Carmen Gomez-Guerrero, PhD (Fundacion Jimenez Diaz University Hospital-Health Research Institute at the Autonomous University of Madrid, in Spain) has discovered a promising new strategy.

The approach targets a cellular pathway called JAK/STAT that is chronically activated in diabetes and mediates the damaging effects of high blood sugar on kidney cells. The researchers developed a compound that mimics a protein called Suppressor Of Cytokine Signaling 1 (SOCS1) that helps regulate JAK/STAT, and they found that it can enter cells, inhibit the deleterious effects of high blood sugar on kidney cells, and slow the progression of kidney disease in diabetic mice. In addition, it was able to protect the kidneys in both early and advanced phases of diabetes, it improved kidney function, and it reduced expression of genes associated with kidney inflammation and scarring. These effects occurred independently of blood glucose levels.

"Our goal is to develop the compound as a novel approach to combat chronic complications of diabetes," said Dr. Gomez-Guerrero. "We plan to initiate preclinical development to support early-phase clinical trials."


Study co-authors include Carlota Recio, PhD, Iolanda Lazaro, PhD, Ainhoa Oguiza, PhD, Laura Lopez-Sanz, MSc, Susana Bernal, BSc, and Julia Blanco, MD, PhD.

Disclosures: Dr. Gomez-Guerrero and Dr. Egido are inventors on a patent application regarding peptide. The authors reported no other financial disclosures.

The article, entitled "Suppressor of cytokine signaling-1 (SOCS1) peptidomimetic limits progression of diabetic nephropathy," will appear online at on September 8, 2016, doi: 10.1681/ASN.2016020237.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 16,000 members representing 112 countries. For more information, please visit or contact us at 202-640-4660.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.